Blood Pressure Treatment May Aid Cognition in Very Early Alzheimer’s

Blood Pressure Treatment May Aid Cognition in Very Early Alzheimer’s
A new analysis of data from a Phase 3 clinical trial testing the blood pressure medication nilvadipine supports evidence that its use helps to slow cognitive decline in Alzheimer's patients with very mild, very early stage disease. This finding was reported earlier  — the trial ended in 2016 — but results then looked at the entire trial population, ranging from people with very early to moderate disease. Supporting the earlier findings may aid in repurposing nilvadipine to prevent the disease in people at risk and to treat very early stage patients. They also again found evidence of  "a greater cognitive decline" in people with moderate Alzheimer's treated with nilvadipine, compared to those in this group given a placebo. The study, “The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial,”  was published in the journal Frontiers in Neurology People with Alzheimer's, the most common neurodeg
Subscribe or to access all post and page content.